AU2017357758B2 - Improved process of preparing mRNA-loaded lipid nanoparticles - Google Patents

Improved process of preparing mRNA-loaded lipid nanoparticles Download PDF

Info

Publication number
AU2017357758B2
AU2017357758B2 AU2017357758A AU2017357758A AU2017357758B2 AU 2017357758 B2 AU2017357758 B2 AU 2017357758B2 AU 2017357758 A AU2017357758 A AU 2017357758A AU 2017357758 A AU2017357758 A AU 2017357758A AU 2017357758 B2 AU2017357758 B2 AU 2017357758B2
Authority
AU
Australia
Prior art keywords
minute
mrna
lipid nanoparticles
solution
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017357758A
Other languages
English (en)
Other versions
AU2017357758A1 (en
Inventor
Zarna BHAVSAR
Frank Derosa
Michael Heartlein
Shrirang KARVE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translate Bio Inc
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Publication of AU2017357758A1 publication Critical patent/AU2017357758A1/en
Application granted granted Critical
Publication of AU2017357758B2 publication Critical patent/AU2017357758B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/03—Carboxy- and carbamoyltransferases (2.1.3)
    • C12Y201/03003—Ornithine carbamoyltransferase (2.1.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04005—Argininosuccinate synthase (6.3.4.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017357758A 2016-11-10 2017-11-10 Improved process of preparing mRNA-loaded lipid nanoparticles Active AU2017357758B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420413P 2016-11-10 2016-11-10
US62/420,413 2016-11-10
US201762580155P 2017-11-01 2017-11-01
US62/580,155 2017-11-01
PCT/US2017/061113 WO2018089801A1 (en) 2016-11-10 2017-11-10 Improved process of preparing mrna-loaded lipid nanoparticles

Publications (2)

Publication Number Publication Date
AU2017357758A1 AU2017357758A1 (en) 2019-05-16
AU2017357758B2 true AU2017357758B2 (en) 2023-11-16

Family

ID=60782328

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017357758A Active AU2017357758B2 (en) 2016-11-10 2017-11-10 Improved process of preparing mRNA-loaded lipid nanoparticles

Country Status (7)

Country Link
US (2) US20180153822A1 (cg-RX-API-DMAC10.html)
EP (1) EP3538073A1 (cg-RX-API-DMAC10.html)
JP (2) JP7738979B2 (cg-RX-API-DMAC10.html)
AU (1) AU2017357758B2 (cg-RX-API-DMAC10.html)
CA (1) CA3041345A1 (cg-RX-API-DMAC10.html)
MA (1) MA46762A (cg-RX-API-DMAC10.html)
WO (1) WO2018089801A1 (cg-RX-API-DMAC10.html)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
WO2016004318A1 (en) * 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
MX2019010155A (es) * 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
HRP20260181T1 (hr) * 2017-10-20 2026-03-27 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
JP7256824B2 (ja) 2018-04-25 2023-04-12 エスリス ゲーエムベーハー 粒子状製剤用の凍結保護剤
EP3793689A1 (en) * 2018-05-15 2021-03-24 Translate Bio, Inc. Subcutaneous delivery of messenger rna
AU2019271215B2 (en) 2018-05-16 2024-09-12 Translate Bio, Inc. Ribose cationic lipids
US12076439B2 (en) 2018-05-24 2024-09-03 Translate Bio, Inc. Thioester cationic lipids
CN118436618A (zh) * 2018-05-30 2024-08-06 川斯勒佰尔公司 信使rna疫苗及其用途
MA52762A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques comprenant une fraction stéroïdienne
EP3802507A1 (en) 2018-05-30 2021-04-14 Translate Bio, Inc. Vitamin cationic lipids
AU2019277355A1 (en) 2018-05-30 2020-12-17 Translate Bio, Inc. Phosphoester cationic lipids
WO2020023533A1 (en) 2018-07-23 2020-01-30 Translate Bio, Inc. Dry power formulations for messenger rna
CA3109548A1 (en) * 2018-08-14 2020-02-20 Ethris Gmbh Lipid-based formulations containing salts for the delivery of rna
MA53443A (fr) * 2018-08-24 2021-12-01 Flagship Pioneering Innovations Vi Llc Paquets de messagers végétaux modifiés et utilisations associées
EP3843709A1 (en) 2018-08-29 2021-07-07 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
EP3849617A1 (en) 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CN112888451A (zh) 2018-10-19 2021-06-01 川斯勒佰尔公司 信使rna的无泵包封
KR102860605B1 (ko) 2018-11-09 2025-09-15 트랜슬레이트 바이오 인코포레이티드 에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
US20220016265A1 (en) 2018-11-09 2022-01-20 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
EP3880174A2 (en) * 2018-11-12 2021-09-22 Translate Bio, Inc. Methods for inducing immune tolerance
WO2020146344A1 (en) 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
EP3911302B1 (en) * 2019-01-17 2025-09-10 Georgia Tech Research Corporation Drug delivery systems containing oxidized cholesterols
CN113939282A (zh) * 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2020214946A1 (en) 2019-04-18 2020-10-22 Translate Bio, Inc. Cystine cationic lipids
EP3959195B1 (en) 2019-04-22 2023-11-08 Translate Bio, Inc. Thioester cationic lipids
WO2020227085A1 (en) 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
AU2020274758B2 (en) * 2019-05-14 2025-05-01 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
EP3976593A1 (en) 2019-05-31 2022-04-06 Translate Bio, Inc. Macrocyclic lipids
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
EP3986858A1 (en) 2019-06-21 2022-04-27 Translate Bio, Inc. Tricine and citric acid lipids
CA3146369A1 (en) * 2019-07-08 2021-01-14 Translate Bio, Inc. Improved mrna-loaded lipid nanoparticles and processes of making the same
AU2020315962B2 (en) 2019-07-23 2026-02-12 Translate Bio, Inc. Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
MX2022007756A (es) 2019-12-20 2022-09-27 Translate Bio Inc Suministro rectal de arn mensajero.
JP2023508881A (ja) * 2019-12-20 2023-03-06 トランスレイト バイオ, インコーポレイテッド Mrna担持脂質ナノ粒子を調製する改善されたプロセス
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
US20230285297A1 (en) * 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
CA3170319A1 (en) 2020-02-10 2021-08-19 Translate Bio, Inc. Methods and compositions for messenger rna purification
BR112022016258A2 (pt) 2020-02-18 2022-10-18 Translate Bio Inc Processos melhorados para transcrição in vitro de rna mensageiro
CN115427021A (zh) * 2020-02-25 2022-12-02 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
CN115667207B (zh) 2020-04-01 2025-09-16 翻译生物公司 基于酚酸脂质的阳离子脂质
WO2021226468A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Improved compositions for cftr mrna therapy
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens
WO2021226463A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
ES3066134T3 (en) 2020-05-14 2026-05-11 Translate Bio Inc Peg lipidoid compounds
JP7873638B2 (ja) 2020-05-15 2026-06-12 トランスレイト バイオ, インコーポレイテッド mRNA送達のための脂質ナノ粒子製剤
TW202220637A (zh) * 2020-08-06 2022-06-01 美商現代公司 製備脂質奈米顆粒之方法
WO2022066916A1 (en) 2020-09-23 2022-03-31 Translate Bio, Inc. Piperazine-based cationic lipids
JP7844452B2 (ja) 2020-09-23 2026-04-13 トランスレイト バイオ, インコーポレイテッド Tesベースのカチオン性脂質
US12678406B2 (en) 2020-10-12 2026-07-14 Translate Bio Inc. Process of preparing ice-based lipid nanoparticles
CA3198411A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
US12576030B2 (en) 2020-11-09 2026-03-17 Translate Bio, Inc. Compositions for delivery of codon-optimized mRNA
EP4304640A1 (en) 2021-03-12 2024-01-17 Northwestern University Antiviral vaccines using spherical nucleic acids
US20250268994A1 (en) 2021-03-25 2025-08-28 Translate Bio, Inc. Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
CA3215606A1 (en) 2021-04-19 2022-10-27 Shrirang KARVE Improved compositions for delivery of mrna
AU2022294274A1 (en) 2021-06-18 2024-02-01 Sanofi Pasteur Inc. Multivalent influenza vaccines
EP4362920A1 (en) 2021-07-01 2024-05-08 Translate Bio, Inc. Compositions for delivery of mrna
WO2023009422A1 (en) * 2021-07-26 2023-02-02 Modernatx, Inc. Processes for preparing lipid nanoparticle compositions for the delivery of payload molecules to airway epithelium
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
JP2024545572A (ja) 2021-11-10 2024-12-10 トランスレイト バイオ, インコーポレイテッド 原発性線毛機能不全の治療のための組成物及び方法
AR127808A1 (es) 2021-11-30 2024-02-28 Sanofi Pasteur Inc Vacunas contra el metapneumovirus humano
CA3242439A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4493548A1 (en) 2022-03-16 2025-01-22 Translate Bio, Inc. Asymmetric piperazine-based cationic lipids
CN121318878A (zh) 2022-04-13 2026-01-13 赛诺菲 基于“古德”缓冲液的阳离子脂质
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
EP4565209A1 (en) 2022-08-04 2025-06-11 Sanofi Pasteur Inc. Quantitative assessment of rna encapsulation
JP2025529906A (ja) 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
US20240108545A1 (en) 2022-10-03 2024-04-04 West Pharmaceutical Services, Inc. Methods and adapters for mixing pharmaceutical complexes
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
KR20250099727A (ko) 2022-11-04 2025-07-02 사노피 파스퇴르 인크 호흡기 세포융합 바이러스 rna 백신접종
TW202428289A (zh) 2022-11-08 2024-07-16 美商歐納醫療公司 環狀rna組合物
AU2023394992A1 (en) 2022-12-15 2025-07-31 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
TW202438514A (zh) 2022-12-20 2024-10-01 法商賽諾菲公司 鼻病毒mrna疫苗
WO2024160826A1 (en) 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne
US20250009865A1 (en) 2023-05-10 2025-01-09 Sanofi Combination respiratory mrna vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
JP2026524781A (ja) 2023-06-12 2026-07-24 サノフイ 芳香族頭部基を有するトリシン及びクエン酸系カチオン性脂質
MX2025015001A (es) 2023-06-12 2026-02-03 Sanofi Sa Lipidos cationicos basados en tricina y acido citrico
JP2026524780A (ja) 2023-06-12 2026-07-24 サノフイ 芳香族頭部基を有するステロール系カチオン性脂質
JP2026524354A (ja) 2023-06-28 2026-07-22 サノフィ ワクチンズ ユーエス インコーポレイテッド 核酸送達のためのジアンヒドロヘキシトール系イオン化可能な脂質
JP2026524414A (ja) 2023-06-28 2026-07-22 サノフィ ワクチンズ ユーエス インコーポレイテッド 核酸送達のためのヘルパー脂質
WO2025003760A1 (en) 2023-06-28 2025-01-02 Sanofi Sterol analogs in lipid nanoparticle formulations
IL325951A (en) 2023-07-19 2026-03-01 Sanofi Sa Porphyromonas gingivalis antigenic constructs
TW202527960A (zh) 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾b型流感血球凝集素多肽及核酸及其用途
EP4780812A1 (en) 2023-09-20 2026-07-29 Sanofi Good" buffer-based cationic lipids for nucleic acid delivery
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025091377A1 (en) * 2023-11-02 2025-05-08 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025101862A1 (en) 2023-11-08 2025-05-15 Axelyf ehf. Single domain antibody binders of myc
WO2025104351A1 (en) 2023-11-17 2025-05-22 Sanofi Pasteur Inc. Hplc-based assays for detecting multiple mrna constructs
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025134071A1 (en) 2023-12-22 2025-06-26 Sanofi Malic and glutaric acid based ionizable lipids
AU2024412236A1 (en) 2023-12-28 2026-07-09 Fujifilm Corporation Method for delivering nucleic acid to immune cells, agent for delivering nucleic acid to immune cells, and use thereof
WO2025141521A1 (en) 2023-12-29 2025-07-03 Sanofi Lipids having dendritic moieties
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2025261607A1 (en) 2024-06-21 2025-12-26 BioNTech SE Particles, compositions and methods
WO2026006524A2 (en) 2024-06-26 2026-01-02 Sanofi Pasteur Inc. Bis-ester and amide cationic lipids
WO2026003373A1 (en) 2024-06-28 2026-01-02 Sanofi Phenolic acid lipid based cationic lipids
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026027730A1 (en) 2024-07-31 2026-02-05 Sanofi Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
WO2026033123A1 (en) 2024-08-08 2026-02-12 Sanofi Pasteur Inc. Lipid nanoparticle formulations for mrna delivery
WO2026053147A1 (en) 2024-09-05 2026-03-12 Sanofi Pasteur Inc. Helper lipids and lnp compositions comprising same
WO2026052773A1 (en) 2024-09-06 2026-03-12 Sanofi Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
WO2026094020A1 (en) 2024-11-04 2026-05-07 Sanofi Pasteur Inc. Phthalic acid and vanillic acid based cationic lipids
WO2026101699A1 (en) * 2024-11-08 2026-05-15 R.P. Scherer Technologies, Llc Lipid nanoparticle formulations, and methods of use thereof
WO2026104670A1 (en) 2024-11-15 2026-05-21 Sanofi Pasteur Variants of epstein-barr virus glycoprotein b, nucleic acids encoding the same, and uses thereof
WO2026112284A1 (en) 2024-11-20 2026-05-28 President And Fellows Of Harvard College Lipid particles for delivering rna vaccines
WO2026122418A1 (en) 2024-12-02 2026-06-11 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2026143002A2 (en) 2024-12-23 2026-07-02 Sanofi Pasteur Inc. Dianhydrohexitol based ionizable lipids for nucleic acid delivery
WO2026142992A1 (en) 2024-12-23 2026-07-02 Sanofi Pasteur Inc. Lipid nanoparticle formulations
WO2026153419A1 (en) * 2025-01-16 2026-07-23 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle compositions and processes of preparing the same
WO2026165320A1 (en) 2025-01-31 2026-08-06 Sanofi Vaccines US Inc. Morpholino cationic lipids
WO2026165530A1 (en) 2025-02-03 2026-08-06 Renagade Therapeutics Management Inc. Hydrophilic polymer lipids for use in lipid nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003709A1 (en) * 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US7094423B1 (en) * 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US20150110857A1 (en) * 2013-10-22 2015-04-23 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
WO2015128030A1 (en) * 2014-02-26 2015-09-03 Ethris Gmbh Compositions for gastrointestinal administration of rna
EP3020701A1 (en) * 2013-07-08 2016-05-18 Daiichi Sankyo Company, Limited Novel lipid

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
JP2599492B2 (ja) * 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6897200B1 (en) * 1998-10-14 2005-05-24 University Of Kentucky Research Foundation Oligonucleotide delivery systems for camptothecins
ATE397488T1 (de) * 1998-11-13 2008-06-15 Heriot William A Vorrichtung zur herstellung von liposomen
WO2001005373A1 (en) * 1999-07-15 2001-01-25 Inex Pharmaceuticals Corp. Methods and apparatus for preparation of lipid vesicles
EP1202714A1 (en) * 1999-07-16 2002-05-08 Purdue Research Foundation Vinyl ether lipids with cleavable hydrophilic headgroups
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2008031230A1 (en) * 2006-09-15 2008-03-20 Dalhousie University Methods of determining susceptibility of cells to reovirus infection and methods for treating cellular proliferative disorders with reovirus
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
EP2787977A4 (en) * 2011-12-09 2015-05-06 Univ California LIPOSOMAL ACTIVE INVERTING
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10258698B2 (en) * 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
WO2016004318A1 (en) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US20180237849A1 (en) * 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003709A1 (en) * 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US7094423B1 (en) * 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
EP3020701A1 (en) * 2013-07-08 2016-05-18 Daiichi Sankyo Company, Limited Novel lipid
US20150110857A1 (en) * 2013-10-22 2015-04-23 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
WO2015128030A1 (en) * 2014-02-26 2015-09-03 Ethris Gmbh Compositions for gastrointestinal administration of rna

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Love, KT et al., "Lipid-like materials for low-dose, in vivo gene silencing." Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(5):1864-9 *

Also Published As

Publication number Publication date
AU2017357758A1 (en) 2019-05-16
JP2019533707A (ja) 2019-11-21
US20240041789A1 (en) 2024-02-08
MA46762A (fr) 2019-09-18
CA3041345A1 (en) 2018-05-17
JP7881520B2 (ja) 2026-06-29
WO2018089801A1 (en) 2018-05-17
JP7738979B2 (ja) 2025-09-16
US20180153822A1 (en) 2018-06-07
EP3538073A1 (en) 2019-09-18
JP2023166489A (ja) 2023-11-21

Similar Documents

Publication Publication Date Title
US20240041789A1 (en) Process of Preparing mRNA-Loaded Lipid Nanoparticles
AU2020274758B2 (en) Improved process of preparing mRNA-loaded lipid nanoparticles
US12064515B2 (en) Process of preparing mRNA-loaded lipid nanoparticles
US20250025430A1 (en) Process of preparing mrna-loaded lipid nanoparticles
US20240366798A1 (en) Processes of preparing mrna-loaded lipid nanoparticles
EP3900702A1 (en) Mrna therapy for pompe disease
WO2022081548A9 (en) Improved process of preparing ice-based lipid nanoparticles
RU2832672C2 (ru) УЛУЧШЕННЫЙ СПОСОБ ПОЛУЧЕНИЯ ЛИПИДНЫХ НАНОЧАСТИЦ, ЗАГРУЖЕННЫХ мРНК

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)